Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Molecular Characterization of the Progressive Landscape of Depression.

bioRxiv : the preprint server for biology·2026
Same author

Re-thinking neuropeptide therapeutics: What Neuropeptide Y and Galanin teach us about stress, resilience, and drug design.

Neuropeptides·2026
Same author

Region-dependent differences in tonic inhibition underlie epileptic features in Angelman syndrome model mice.

Epilepsia·2026
Same author

The α5-Containing GABA<sub>A</sub> Receptor as a Target for Disorders of Altered Dendritic Inhibition.

Biological psychiatry·2026
Same author

Prevention of microglial activation and postoperative cognitive deficits by positive allosteric modulation of α5-GABA<sub>A</sub> receptors.

British journal of pharmacology·2026
Same author

Influences of subtle NMDA receptor blockade and allosteric modulation of α5 GABAA receptors on reward-related impulsivity in rats.

Psychopharmacology·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Jingxin Chen1, Carla Elena Mezo-Gonzalez1, Michael D Marcotte1

  • 1Centre for Addiction and Mental Health, Toronto, ON, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La modulación alostérica positiva de los α5-GABAARs por GL-II-73 mejoró la función cognitiva en un modelo murino de la enfermedad de Alzheimer. Estos hallazgos confirman el mecanismo de acción del fármaco a través del sitio de unión de las benzodiazepinas.

Palabras clave:
Enfermedad de AlzheimerReceptores GABA-AModulación alostéricaFunción cognitivaDesarrollo de fármacosModelos animalesMemoria de trabajoCognición espacialGL-II-73

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurociencia; Farmacología

Sus antecedentes:

  • La enfermedad de Alzheimer (EA) carece de tratamientos eficaces.; Los receptores GABAA que contienen alfa5 (α5-GABAARs) son cruciales para la función cognitiva y un objetivo terapéutico.; GL-II-73, un modulador de α5-GABAAR, mostró potencial en modelos preclínicos, pero su mecanismo preciso requería validación.

Objetivo del estudio:

  • Demostrar la necesidad de la modulación alostérica positiva de los α5-GABAARs por GL-II-73 para la regulación de la función cognitiva.; Investigar el mecanismo de acción de GL-II-73 en un modelo murino transgénico doble de EA.

Principales métodos:

  • Se generaron ratones transgénicos dobles (5xFAD x α5-KI) que exhiben patología amiloide y α5-GABAARs insensibles a los fármacos.; Se administró GL-II-73 (30 mg/kg) durante tres semanas a ratones transgénicos dobles y a sus compañeros de camada de tipo salvaje.; Se evaluó la memoria de trabajo y la cognición espacial utilizando las tareas del laberinto en Y y del agua de Morris.

Principales resultados:

  • Los ratones sensibles a los fármacos tratados con GL-II-73 exhibieron un mejor rendimiento tanto en tareas de memoria de trabajo como de cognición espacial.; No se observaron mejoras cognitivas en ratones insensibles a los fármacos tratados con GL-II-73, a pesar de una patología amiloide similar.

Conclusiones:

  • Los efectos de mejora cognitiva de GL-II-73 se median por la modulación alostérica del sitio de unión de las benzodiazepinas de los α5-GABAARs.; Este estudio confirma el potencial terapéutico de dirigirse a los α5-GABAARs para mejorar los déficits cognitivos en la enfermedad de Alzheimer.